MLchartDataset catalogue

MDM2 antagonist ASTX295

Term · Oncology and biomedicine · MLC-T-ONC-015039

An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.

Table 1. Record
IdentifierMLC-T-ONC-015039
FieldOncology and biomedicine
SynonymsMDM2 inhibitor ASTX295
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015039",
  "term": "MDM2 antagonist ASTX295",
  "field": "Oncology and biomedicine",
  "definition": "An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.",
  "synonyms": [
    "MDM2 inhibitor ASTX295"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mdm2-antagonist-astx295/"
}

Record 10,702 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.